Mabuchi, 2017, Half a century tales of familial hypercholesterolemia (FH) in Japan, J Atheroscler Thromb, 24, 189, 10.5551/jat.RV16008
Harada-Shiba, 2010, Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia, J Atheroscler Thromb, 17, 667, 10.5551/jat.4143
van der Graaf, 2008, Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia, J Am Coll Cardiol, 52, 1421, 10.1016/j.jacc.2008.09.002
Dufour, 2019, Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: results from an open-label extension of the ODYSSEY LONG TERM trial, J Clin Lipidol, 13, 138, 10.1016/j.jacl.2018.11.007
Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur Heart J, 34, 10.1093/eurheartj/eht273
Tada, 2015, Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography, Am J Cardiol, 115, 724, 10.1016/j.amjcard.2014.12.034
Tada, 2017, Assessments of carotid artery plaque burden in patients with familial hypercholesterolemia, Am J Cardiol, 120, 1955, 10.1016/j.amjcard.2017.08.012
Tada, 2017, Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia, Eur Heart J, 38, 1573, 10.1093/eurheartj/ehx004
Harada-Shiba, 2018, Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017, J Atheroscler Thromb, 25, 751, 10.5551/jat.CR003
Tada, 2018, Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease, J Clin Lipidol, 12, 1436, 10.1016/j.jacl.2018.08.006